JP6444984B2 - プロポリス抽出物を含む治療組成物およびその使用 - Google Patents

プロポリス抽出物を含む治療組成物およびその使用 Download PDF

Info

Publication number
JP6444984B2
JP6444984B2 JP2016506281A JP2016506281A JP6444984B2 JP 6444984 B2 JP6444984 B2 JP 6444984B2 JP 2016506281 A JP2016506281 A JP 2016506281A JP 2016506281 A JP2016506281 A JP 2016506281A JP 6444984 B2 JP6444984 B2 JP 6444984B2
Authority
JP
Japan
Prior art keywords
composition
propolis
cancer
hydroxyl
gastrointestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016506281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515615A (ja
JP2016515615A5 (enExample
Inventor
ケリー ポール
ケリー ポール
オーウェン キャッチポール
オーウェン キャッチポール
ケビン ミッチェル
ケビン ミッチェル
Original Assignee
マヌカ ヘルス ニュージーランド リミテッド
マヌカ ヘルス ニュージーランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マヌカ ヘルス ニュージーランド リミテッド, マヌカ ヘルス ニュージーランド リミテッド filed Critical マヌカ ヘルス ニュージーランド リミテッド
Publication of JP2016515615A publication Critical patent/JP2016515615A/ja
Publication of JP2016515615A5 publication Critical patent/JP2016515615A5/ja
Application granted granted Critical
Publication of JP6444984B2 publication Critical patent/JP6444984B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016506281A 2013-04-05 2014-04-07 プロポリス抽出物を含む治療組成物およびその使用 Active JP6444984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ609106 2013-04-05
NZ60910613 2013-04-05
PCT/NZ2014/000059 WO2014163512A1 (en) 2013-04-05 2014-04-07 Therapeutic compositions comprising extracts of propolis and uses thereof

Publications (3)

Publication Number Publication Date
JP2016515615A JP2016515615A (ja) 2016-05-30
JP2016515615A5 JP2016515615A5 (enExample) 2017-07-06
JP6444984B2 true JP6444984B2 (ja) 2018-12-26

Family

ID=51658695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506281A Active JP6444984B2 (ja) 2013-04-05 2014-04-07 プロポリス抽出物を含む治療組成物およびその使用

Country Status (7)

Country Link
US (1) US20160030364A1 (enExample)
EP (1) EP2981254B1 (enExample)
JP (1) JP6444984B2 (enExample)
CN (1) CN105163728B (enExample)
AU (1) AU2014250138B2 (enExample)
TW (1) TW201517901A (enExample)
WO (1) WO2014163512A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983681B1 (en) 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof
TW201609113A (zh) * 2014-07-18 2016-03-16 歐文 約翰 蓋奇波 治療組合物及其用途
RU2568876C1 (ru) * 2015-02-11 2015-11-20 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ определения оксима пиностробина в плазме крови
JP2019515943A (ja) * 2016-03-24 2019-06-13 マヌカ ヘルス ニュージーランド リミテッド 治療用組成物およびその使用
CN106913873A (zh) * 2017-04-26 2017-07-04 中国药科大学 巴西绿蜂胶在制备pdt抗肿瘤的协同增效药物中的应用
WO2020086830A2 (en) * 2018-10-26 2020-04-30 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
US20220370385A1 (en) * 2019-09-17 2022-11-24 Enzene Biosciences Ltd. Compositions for use in inhibiting src kinase and treating and preventing associated disorders
CN116492324A (zh) * 2023-01-04 2023-07-28 河南科技大学第一附属医院 咖啡酸在预防和治疗结直肠癌中的应用、含咖啡酸的药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO2002047615A2 (en) * 2000-12-13 2002-06-20 University Of Rochester Oral compositions and use thereof
US6689811B2 (en) * 2001-04-20 2004-02-10 Wake Forest University Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers
JP2003119169A (ja) * 2001-07-30 2003-04-23 Shigetoshi Kadota 細胞毒性活性を有する化合物およびそれを有効成分とする医薬組成物
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
KR100968367B1 (ko) * 2006-10-02 2010-07-06 재단법인서울대학교산학협력재단 카페인산 유도체 및 이를 유효성분으로 포함하는 조성물
CN101502506B (zh) * 2009-02-24 2011-08-17 连晓媛 咖啡酸3,4-二羟基苯乙酯的医药用途
WO2011156889A1 (en) * 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
CN101875648B (zh) * 2010-07-12 2012-12-12 马灵媛 一种从药用植物中提取纯化球松素的方法及其药物制剂与应用
WO2013022740A2 (en) * 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
WO2013078371A2 (en) * 2011-11-22 2013-05-30 The Johns Hopkins University Methods and compositions for reducing alcohol toxicity
CN102949384A (zh) * 2012-10-29 2013-03-06 浙江大学 咖啡酸3，4-二羟基苯乙酯在制备抗肿瘤药物中的应用
CN104016862A (zh) * 2013-02-28 2014-09-03 北京大学 咖啡酸苯乙酯酚羟基保护衍生物的制备及其作为神经保护剂和抗肿瘤药物的应用
EP2983681B1 (en) * 2013-04-05 2020-07-15 Manuka Health New Zealand Limited Therapeutic compositions and uses thereof

Also Published As

Publication number Publication date
EP2981254A1 (en) 2016-02-10
EP2981254A4 (en) 2017-01-11
CN105163728A (zh) 2015-12-16
AU2014250138B2 (en) 2018-11-15
AU2014250138A1 (en) 2015-11-19
HK1215859A1 (zh) 2016-09-23
EP2981254B1 (en) 2018-10-10
TW201517901A (zh) 2015-05-16
WO2014163512A1 (en) 2014-10-09
JP2016515615A (ja) 2016-05-30
US20160030364A1 (en) 2016-02-04
CN105163728B (zh) 2018-10-02

Similar Documents

Publication Publication Date Title
JP6444984B2 (ja) プロポリス抽出物を含む治療組成物およびその使用
US10420804B2 (en) Therapeutic compositions and uses thereof
AU2023202398B2 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
AU2023201100B2 (en) Therapeutic compositions and uses thereof
US9820963B2 (en) Composition containing lignan compound as active ingredient for preventing or treating cancer
HK1215859B (en) Therapeutic compositions comprising extracts of propolis and uses thereof
HK1220920B (zh) 治疗性组合物和其用途
HK1261075B (en) Therapeutic compositions and uses thereof
HK1261075A1 (en) Therapeutic compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170525

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181128

R150 Certificate of patent or registration of utility model

Ref document number: 6444984

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250